- Home
- CSTL vs VMO Comparison
CSTL vs VMO Comparison
Compare CSTL & VMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- VMO
- Stock Information
- Founded
- CSTL 2007
- VMO 1992
- Country
- CSTL United States
- VMO United States
- Employees
- CSTL N/A
- VMO N/A
- Industry
- CSTL Medical Specialities
- VMO Trusts Except Educational Religious and Charitable
- Sector
- CSTL Health Care
- VMO Finance
- Exchange
- CSTL Nasdaq
- VMO Nasdaq
- Market Cap
- CSTL 661.7M
- VMO 652.2M
- IPO Year
- CSTL 2019
- VMO N/A
- Fundamental
- Price
- CSTL $33.02
- VMO $9.66
- Analyst Decision
- CSTL Strong Buy
- VMO
- Analyst Count
- CSTL 6
- VMO 0
- Target Price
- CSTL $38.67
- VMO N/A
- AVG Volume (30 Days)
- CSTL 421.5K
- VMO 254.7K
- Earning Date
- CSTL 11-03-2025
- VMO 01-01-0001
- Dividend Yield
- CSTL N/A
- VMO 4.39%
- EPS Growth
- CSTL N/A
- VMO N/A
- EPS
- CSTL N/A
- VMO N/A
- Revenue
- CSTL $343,530,000.00
- VMO N/A
- Revenue This Year
- CSTL N/A
- VMO N/A
- Revenue Next Year
- CSTL N/A
- VMO N/A
- P/E Ratio
- CSTL N/A
- VMO N/A
- Revenue Growth
- CSTL 10.15
- VMO N/A
- 52 Week Low
- CSTL $14.59
- VMO $7.86
- 52 Week High
- CSTL $34.64
- VMO $9.87
- Technical
- Relative Strength Index (RSI)
- CSTL 81.56
- VMO 49.99
- Support Level
- CSTL $23.31
- VMO $9.63
- Resistance Level
- CSTL $34.36
- VMO $9.78
- Average True Range (ATR)
- CSTL 1.50
- VMO 0.08
- MACD
- CSTL 1.08
- VMO -0.02
- Stochastic Oscillator
- CSTL 89.19
- VMO 30.56
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About VMO Invesco Municipal Opportunity Trust
Invesco Municipal Opportunity Trust is a diversified, closed-end management investment company. The investment objective of the company is to provide common shareholders with a high level of current income exempt from federal income tax, consistent with preservation of capital.